Olesoxime (TRO19622) is the lead compound of the Trophos’ proprietary cholesterol-oxime compound family of mitochondrial pore modulators. The 24-month randomized, parallel group, double-blind, placebo controlled trial will compare
In return for the license, Colby will pay to Juvaris cash, development-related milestones and royalties on product sales. In addition, Colby will bear all development and commercialization-related expenses
PharmAthene’s rPA anthrax vaccine program has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Disease, National Institutes of
The placebo-controlled study will recruit up to 33 individuals in one or two countries. Roche Neurosciences Disease Translational Area global head Luca Santarelli said their strategy at Roche
IBM will develop the base Watson healthcare technology on which WellPoint’s solution will run. Watson, named after IBM founder Thomas Watson, is a computing system that is designed
The company has developed the SMS to programmatically populate and update the patient information and visit schedule to reduce site workload and improve adoption rates throughout the study.
Everolimus treats patients aged 3 years and older who require therapeutic intervention but are not amenable to surgery. Everolimus targets mTOR, a protein that acts as a regulator
Sucampo will have exclusive commercial rights to any biologic products successfully developed and commercialized in the course of the collaboration. The agreement allows Numab to receive up to
The funding will be used in multiple animal efficacy studies as well as human safety studies to further demonstrate the utility of Anthim (ETI-204), to prevent disease and
The double-blind, dose-ranging, multi-center, parallel group, randomized study was designed to evaluate the safety and efficacy of taliglucerase alfa in 31 treatment-naive patients suffering from Gaucher disease. Patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.